Two months after its CFO abruptly resigned, Arch Therapeutics, a Framingham-based biotechnology company, has filed for Chapter 11 bankruptcy. The firm filed for voluntary bankruptcy on April 18, ...

Arch Therapeutics Inc. has filed for Chapter 11 bankruptcy protection, citing “capital market challenges” as a major factor leading up to the filing. Moderna sues construction firm claiming leaks, ...

Wound products developer Arch Therapeutics (ARTH) has filed to uplist its shares to Nasdaq and raise around $35M through an offering of stock and warrants. The company's shares are currently traded ...